p53 and Zinc: A Malleable Relationship.
Level 5 - mechanism / opinion, no new human data
Narrative review of biophysical and pharmacological mechanisms without original human data
PubMed 35495631 · doi:10.3389/fmolb.2022.895887
What was done
Narrative review evaluating biophysical and pharmacological literature on the zinc dependence of p53. The authors describe p53 conformational malleability at 37°C, how zinc dysregulation and oncogenic mutations induce misfolding, and the mechanisms of synthetic metallochaperones compared to other clinical-stage mutant p53-targeted drugs.
What was found
The abstract reports no empirical numbers or quantitative effect sizes. Qualitatively, folded p53 binds zinc tightly but becomes intrinsically unstable in the absence of zinc at 37°C. Cellular zinc availability dictates wild-type folding, while zinc loss or oncogenic mutations cause misfolding and loss of tumor-suppressing activity, which can be restored by synthetic metallochaperones.
Why it matters
It highlights p53 structural instability as a reversible biophysical defect, clarifying the mechanistic basis for using zinc metallochaperones to therapeutically reactivate mutant p53 in cancer.
Limits
Narrative review design without systematic search criteria or pooled quantitative data. No original human trial outcomes, clinical efficacy rates, safety parameters, or specific patient populations are reported in the abstract.
Cited by
- supports The tumor suppressor protein p53 requires zinc to function properly.